(12) EX PARTE REEXAMINATION CERTIFICATE (6829th)
`United States Patent
`(10) Number:
`US 6,331,415 C1
`Cabilly et al.
`(45) Certificate Issued:
`May 19, 2009
`
`US00633 l4l5Cl
`
`(54) METHODS OF PRODUCING
`llV[lV[UNOGl.OBUl,lNS, VECTORS AND
`TRANSFORMED HOST CELLS FOR USE
`
`(75)
`
`lnventorsz Shmuel Cabilly, Monrovia, CA (US);
`.
`Herbert-L-. Heyneker, Burlingarne, CA
`(US); William E. Holmes, Pacilica, CA
`(US); Arthur D. Riggs, T1aVerne, CA
`(US); Ronald B. VVetzel, San Francisco,
`CA (US)
`
`(73) Assignees: Genentech, Inc., South San Francisco,
`CA (Us), City of Hope, Duarte, CA
`(US)
`.
`.
`Reexamination Request:
`No. 90/007,542, May 13, 2005
`No. 90/007,859, Dec. 23, 2005
`Reexamination Certificate for:
`Patent NO.Z
`6,331,415
`Issued;
`Dec. 18, 2001
`Appl. No_;
`07/205,419
`
`4,792,447 A
`4,319,567 A
`4,965,196 A
`:=3:1a;:::
`2
`,
`,
`._
`5,179,017 A
`5,225,538 A
`5,336,603 A
`5,420,020 A
`5,428,130 A
`5,455,165 A
`
`5,500,362 A
`,
`,
`2
`5,583,013 A
`5,585,089 A
`.
`‘§’2‘1’Z’?§‘§ 2
`5:648:37 A
`5,686,072 A
`57211103 A
`5,736,137 A
`5,807,715 A
`5,840,545 A
`,
`,._
`
`12/1988 Uhr et al.
`3/:1939 Cab_i11Y et 31‘
`10//1990 Levinson et 31.
`;1,1::2:1;a::;:1
`gape“ 6 a1’
`1
`allas
`1/1993 Axel et al.
`7/1993 C/apcn 6 31.
`8/1994 Capon e al.
`5/1995 Riggs
`6/1995 Capone al.
`10/1995 Capon e :11.
`
`3/1996 Robinson Ct 211.
`/
`FOVV Cy
`Eapolll e a1~
`12/1996 Itakura
`12/1996 Queene al.
`,
`.,
`311339 €}i11‘2?‘;".
`7,1997 Cm,
`.
`11/1997 U11‘
`t
`2/1993 R01,1::,n 91 31,
`4/1998 Anderson et al.
`9/1998 Morrison et al.
`ll/1998 Moorc
`1
`air e a .
`
`Certificate of Correction issued Jun. 25, 2002.
`Related U.S. Application Data
`_
`_
`_
`5
`_
`_
`(63) Continuation of application No. 06/483,457, filed on Apr. 8,
`1983’ “OW P‘1‘~N°« 4-»315s>‘57~
`Int_ CL
`C12]V15/13
`CNN 15/0”
`CIZN 15/63
`
`(2006.01)
`(2006-01)
`(2006.01)
`
`(51)
`
`EP
`
`/_
`
`,
`
`,
`
`zxilfifimn at al.
`2
`al.
`E1-£::r et
`2
`3
`9/2000 Robinson et al.
`6,120,767 A
`3/2001 Robinson et a1.
`6,204,023 B1
`12/2001 Cabilly etal.
`6,331,415 B1
`91/.3002 Aiiel et a1.
`6,453,275 B1
`41_003 Winter
`6,548,640 131
`FOREIGN PATENT DOCUMENTS
`0 036 776
`3/1981
`
`............... .. 435/69.6; 435/252.1; 435/252.3;
`(52) U.S. C1.
`435/252.33; 435/254.11; 435/254.2; 435/254.21;
`435/69.7; 435/70.21; 435/71.2; 435/71.1;
`435/70.1; 435/320.1; 435/455; 435/483;
`435/485; 435/471; 435/69.1
`h ...................... ..N
`585 F'ld fCl..'fi
`t’
`S
`)
`SQ: ap‘;)hCa*t':O:1l ficl: ‘ff:C::1l;ctC Search historv
`one
`"
`.
`References Cited
`U.S. PATENT DOCUMENTS
`_
`9/1980 Viza
`
`(
`
`(56)
`
`4,224,404 A
`
`4,348,376 A
`4,366,246 A
`4,370,417 A
`4,399,216 A
`4,419,446 A
`4,431,740 A
`4,440,859 A
`4s500»537 A
`4'511‘502 A T
`4’565’785 A
`4,599,197 A
`4,634,665 A
`4,642,334 A
`4553.629 A
`4,713,339 A
`4,766,075 A
`
`9/1982 Goldenberg
`12/1982 Riggs
`1/1983 Hung
`8/1983 Axel er al.
`12/1983 Howley
`2/1984 Bell
`4/1934 RUHCI
`2/1985 N‘3Vi11°-. J1 6* 31-
`4/1985 Bui1der°t"’l'
`1/1986 Gilbert
`7/1986 Wetzel
`1/1987 Axel et al.
`2/1987 Moore
`5/1937 Kapum 1,1111.
`12/1987 Leviiisoii et al.
`8/1988 Goeddel et 31.
`
`0 03444333
`“
`
`(confinued)
`
`OTHER PUBLlCAT1ONS
`.
`Harvard .l(ill1’:al ofLaw & Technology 17(2) (Spring 2004),
`pp. 583—6 8.
`Jun. 5, 1995 preliminary amendment in the Moore U.S.
`Appl. No. 08/461,071.,‘
`Declaration of Dr. Richard Axel, submitted Oct. 5, 1989 in
`U.S.App1. No. 08/422,187.*
`
`(Continued)
`~
`~
`~
`,
`~
`Przmaijt Examiner Padniashri Ponnaluri
`(57)
`ABSTRACT
`
`The invention relates to processes for producing, an ii11iiiuiio-
`globulin or an irnrnunologically functional iminurioglobulin
`fragment containing at lcast thc variable domains of thc
`irnmuno lobulin hea
`and light chains The rocesses can
`V
`g
`,h. _h
`d _
`‘b [1151 h V
`V
`1 d
`95° “He 9’ “M? V“ °“ “ 1° Pr.” '4‘? °
`6. ,°‘‘V.’ 4“
`l1glit chains or lragments thereot in a single cell. lhe inven-
`tion also relates to the vectors used to produce the immuno-
`globulin or fragment, and to cells transformed with the vec-
`tors.
`
`Sanofi/Regeneron Ex. 1026, pg 810
`
`Mylan Ex. 1026, pg 810
`
`

`
`US 6,331,415 C1
`Page 2
`
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`W0
`W0
`WO
`W0
`W0
`W0
`W0
`WO
`W0
`W0
`WO
`
`FORE1GN PATENT DOCUMENTS
`060057
`9/1982
`0114506
`12/1983
`102634
`3/1984
`0171496
`2/1986
`173494
`3/1986
`177343
`4/1986
`365997
`5/1990
`0481790
`4/1992
`81/02426
`9/1981
`VVO 82/03088
`9/1982
`83/00164
`1/1983
`87/02671
`5/1987
`89/00999
`2/1989
`89/01783
`3/1989
`92/16553
`10/1992
`93/07899
`4/1993
`93/10817
`6/1993
`93/21319
`10/1993
`97/30087
`8/1997
`
`OTHER PUBLlCAT1ONS
`
`Accolla et al., Proc. Nat’lAcad. Sci. USA 772563 (1980).
`Rice and Baltimore, Proc. Nat’l Acad. Sci. USA 79:7862
`(1982).
`Deacon et al., Antibody Synthesis in Xenopus Ooeytes with
`Messenger Ribonucleic Acid from lmmunized Rats, Bio-
`chemical Society Transactions, vol. 4, pp. 818-820 (1976).
`Ochi et al., Transfer of a cloned immunoglobulin lightwhain
`gene to mutant hybridoma cells restores specific antibody
`production, Nature, vol. 302, pp. 340342 (1983).
`Oi et al., lmmunoglobulin gene expression in transformed
`lymphoid cells, Proc. Natl. Acad. Sci. USA, vol. 80, pp.
`825-829 1983).
`Rice et a ., Regulated expression for an inmiunoglobulin K
`gene introduced into a mouse lymphoid cell line, Proc. Natl.
`Acad. Sci. USA, vol. 79, pp. 7862-7865 (1982).
`Valle eta ., Synthesis and secretion of mouse im111unoglobu-
`lin chains from Xenopus oocytes, Nature, vol. 291, pp.
`338-340 1981).
`Valle et al., Antiwvalbumin monoclonal antibodies interact
`with their antigen in internal membranes of Xenopus
`oocytes, Nature, vol. 300, pp. 71-74 (1982).
`U.S. App .No. 07/233,430, Boss et al.
`U.S. App .No. 07/930,821, Boss et al.
`U.S. App .No. 08/320,381, Boss et al.
`U.S. App . No. 08/450,727, Boss et al.
`U.S. App . No. 08/452,420, Boss et al.
`US. App . No. 08/453,449, Boss et al.
`Abbas et al., Cellular and Molecular lmmunology, Second
`Edition pa. 38-39 (1994).
`Abstract, Journal of Nuclear Medicine, May 1990, No. 613
`(Exhibit
`177, 1nt.No. 104,532).
`Abstract, The Society of Nuclear Medicine 37”’ Annual
`Meeting, Washington Convention Center—Washington,
`D.C., Tuesday, Jun. 19-Friday, Jun. 22, 1990 (Exhibit 1 180,
`1nt.No. 104,532).
`Abstract, World Federation of Nuclear Medicine & Biology,
`Abstract submitted Jan. 15, 1990 (Exhibit 1178,
`lnt. No.
`104,532).
`Achord et al. 1978. Human lkglucuronidasez in vivo clear-
`ance and in vitro uptake by a glycoprotein recognition sys-
`tem on reticuloendothelial cells. Cell 15:269-278.
`Alberts et al. Molecular Biology of The Cell, pp. 285 and
`375. Garland Publishing, lnc., (1983).
`
`Alberts, B. Molekularbiologie der Zelle, Weinheim: VCH p.
`1075 (1987).
`Alt et al. “lmmunoglobulin heavywhain expression and
`class switching iii a muri11e leukaemia cell line,” Nature, vol.
`298, p. 325-31, (Mar. 25, 1982).
`Andrews, DW. and J.D. Capra. 1980. Clinical 1mmnnobio1-
`ogy. pp. 1-18, W.B. Sanders.
`Arathoon, et a1.—Large-Scale Cell Culture in Biotechnol-
`ogy pp. 139(Ll395, Science, vol. 232, Jun. 1986 (Exhibit
`1157; lnt. No. 104,532).
`Arthritis & Rheumatism, Abstract Suppl. vol. 39, No. 9, Sep.
`1996, p. S244.
`Ashford et al. 1993 “Site-specific Glycosylation of Recom-
`binant Rat and Human Soluble CD4 Variants Expressed in
`Chinese Hamster Ovary Cells”,
`J. Biol. Chem., 268.
`3260-3267.
`Bagdasarian et al., “Activity of the hybrid trp-lac (tac) pro-
`moter of putida. Construction of broad-host-range, con-
`trolledwxpression vectors” Gen 26 (2-3): 273-282 (Dec.
`1983).
`Baldwin, R.W. et al. 1990. Monoclonal Antibodies and
`lmmunoconjugates. The Parthenon Publishing Group (UK),
`p.209.
`Banerji et al., “A Lymphocyte-Specific Cellular Enhancer ls
`Located Downstream of the Joining Region in 1mmLmoglo—
`bulin Heavy Chain Genes,” Cell, vol. 33. 729-740 (Jul.
`1982).
`J. Baselga et al., “Recombinant Humanized Anti-HER2
`Antibody (11erceptinTM) Enhances the Antitnmor Activity of
`Paelitaxel and Doxorubicin against HER2/neu 0verexpress—
`ing Human Breast Cancer Xenografts”, Cancer Res. (1988)
`58: 2825-2831.
`Beatty et al., Cancer Research (Suppl). 50:922s-926s (Feb.
`1, 1990) (Exhibit 1011; lnt. No. 104,532).
`Beatty et al., Cancer Research 49:l587-1594 (Mar. 15,
`1989) (Exhibit 1010; lnt. No. 104,532).
`Begent et al., Br. .1. Cancer, 622487 (1990) (Exhibit 1088; lnt.
`No. 104,532).
`Benoist, C., et al., “ln vivo sequence requirements of the
`SV40 early promoter region,” Nature, 290: 304-310 (1981).
`Bergman, Y., et al., “Two regulatory elements for immuno-
`globulin kappa light chain gene expression,” Proc. Natl.
`Acad. Sci., 81: 7041-45 (1984).
`Berrnan eta1., Science. Nov. 4, 1983; 222(4623): 524-7.
`Bemier, “Proliferative Disorders of the lmmune System,”
`Chapter 21 (pp. 622-643) in Bellanti, Immunologv II (1978).
`Bindon et al. (1985). Therapeutic potential of monoclonal
`antibodies to the leukocyte-common antigen. Synergy and
`interference in com plement-mediated lysis. Transplantation
`40(5):53s44 (Exhibit 2072; lnt. No. 104,532).
`Blatt, C. and J. Haimovich. 1981.
`'1he selective effect of
`tunicamycin on the secretion of 1gM and lgG produced by
`the same cells. European Journal Of lmmunology 1 1:65 66.
`Blair, DG, ct al., “Activation of the transforming potential of
`a normal cell sequence: a molecular model for oncogenesis,”
`Science, 212: 941-43 (1981).
`Breathnach. R.. et al. “Corrected splicing of a chicken oval-
`bumin gene transcript in mouse L cells,” Proc. Natl. Acad.
`Sci., 77: 74(L44 (1980).
`Bruggemann et al. 1987. Comparison of the effector f1mc-
`tions of human immunoglobulins using a matched set of
`chimeric antibodies. Journal of Experimental Medicine
`166(5):1351-61 (Exhibit 2079; lnt. No. 104,532).
`
`Sanofi/Regeneron Ex. 1026, pg 811
`
`Mylan Ex. 1026, pg 811
`
`

`
`US 6,331,415 C1
`Page3
`
`Bym, et al., Nature 344:667—670 (Apr. 12, 1990) (Exhibit
`1055; Int. No. 104,532).
`Ir11r11unoglobulir1 trar1-
`Cabilly, S. and A.D. Riggs. 1985.
`scripts and molecular history of a hybridoma that produces
`antibody to carcinocmbryonic antigcn. Gcnc 40(1): 57—61
`(Exhibit 2073; Int. No. 104,532).
`temperatures
`Cabilly, Shmuel, “Growth at subwptimal
`allows the production of ftmctional, antigen—binding Fab
`fragments in Escherichia coli” Gene 85:553—57 (1989).
`Cancer Principles & Practice of Oncology, 5th Edition, Vol.
`1, Chapter 18, pp. 36(L372 (Exhibit 1181; Int. l\o. 104.532).
`Carter et al., “High Level Escherichia cali Expression a11d
`Production of a Bivalent Ilumanized Antibody Fragment.”
`Bio/Technology 10(2):153—167 (Feb. 1992).
`Chang, E., et al.. “Transformation by cloned Harvey sar-
`coma virus DNA: efliciency increased by long terminal
`repeat DNA,” Science, 2 0: 1249—51 (1980).
`Chang ct al., Proc. Na 1. Acad. Sci. USA, vol. 84, pp.
`5640-5644 (1987) (Exhioit 1107; Int. No. 104,532).
`Clynes et al., 2000 “Inhibitory Fc receptors modulate in vivo
`cytoxicity against tumor antigens” Nature Med 6: 443—446.
`Cobbold et al., Bone Marrow Purging and Processing, pp.
`139—154 (Jan. 1, 1990) (Exhibit 1027; Int. No. 104,532).
`Cobbold, S.P. and H. Waldrnann, “Therapeutic potential of
`monovalent
`monoc o11al
`antibodies”
`Nature
`308(5958):460a62 (1984) (Exhibit 2068; Int. No. 104,532).
`Code of Medical Ethics and Current Opinions, excerpts from
`pp. 339—379 GExhibit 2269; Int. No. 104,532).
`Colcher et al., Cancer Res. 49:1738—1745 (1989) (Exhibit
`1047; Ir1t. No. 104,532).
`Crowe, et al., A Clinical Experimental In11nunology, 1992,
`87, pp. 105—110 (Exhibit 1070; Int. No. 104,532).
`Davies, J ., et al., “A new selective agent for eukaryotic clon-
`ing Vectors,” Am J. Trop. Med. Htg, 29 (5 Suppl): 1089 92
`(1980).
`Davis et al. 1990, “High Level Expression in Chinese Ham-
`ster Ovary Cells of Soluble Forms of CD4 T Lymphocyte
`Glycoprotein Including Glycosylation Variants.” J Biol.
`Chem. 265, l0410—10418 (Exhibit 2189; Int. No. 104,532).
`Davis, “Immunoglobulin molecules and genes” Microbiol-
`ogy Including Immunology and Molecular Genetics, Third
`edition, 1980, Chapter 17, pp. 33&379, Harper & Row,
`Ilagerstown, MD.
`De Waele et al. 1988. Expression in non—tym ’)l101d cells of
`mouse recombinant immunoglobulin directed against the
`tumor marker human placental alkaline phosphatase. Euro-
`pean Journal of Biochemistry 176:287—295 (Exhibit 2109;
`l11t. No. 104,532).
`Dean, C.J. 1994. Preparation and characteriza ion of mono-
`clonal antibodies to proteins and other cellular components.
`Methods in Molecular Biology 322361-379 (Exhibit 2026;
`Int. No. 104,532).
`DeBoer, “The tac promoter: A functional hybrid derived
`from the trp and lac Promoters” Proc. Natl. Acad. Sci. USA
`80:2l—25 (1983).
`Devita et al., Cancer: Principles & Practice of Oncology,
`1997, 5th Ed.. vol. 1, Chapter 18, VT. DeVita (Ed.), Lippin-
`cott—Raven, Philadelphia, PA.
`Duda et al., J. Surgical Oncology 44:73—77 (Jun. 1990)
`(Exhibit 1014; Int. No. 104,532).
`Dyer et al., Blood 73:l43l—l439 (May 1, 1989) (Exhibit
`1025; Int. No. 104,532).
`Invest. Drugs
`Emery & Adair, Exp. Opin.
`3(3):241—251 (Exhibit 1087; Int. No. 104,532).
`
`(1994)
`
`Estabrook A. and J. A. K. Patterson, “Innnunotherapy using
`monoclonal antibodies,” J. of Cutaneous Pathology 10:
`559—66 (1983).
`Ettinger, et al. Cancer Treatment Reports vol. 83, No. 1, pp.
`131—134, Jan. 1979 (Exhibit 1129; Int. No. 104,532).
`Finnegan et al., J. Rheumatology 1997, 24:7, 1448—l449
`(Exhibit 1069; Int. No. 104,532).
`Fittler et al., “Localization in Mouse—L—Cell Chromosomal
`Sites of Transferred Immunoglobulin Genes," Chromosoma
`(Berl.) 84, 717—727 (1982).
`(1985)
`5:893—899
`Fleischman,
`J. BioScience Reports
`(Exhibit 1080 Case No. CIV S—0(L1252 WES GGII).
`Frenkel et al. 1980. Analysis and detection of B cell neo-
`plasms. Blood Cells 6:783—793 (Exhibit 2123; Int. No. 104,
`532).
`Friend et al., Transplantation 48:248—253 (Aug. 1, 1989)
`(Exhibit 1023; Int. No. 104,532).
`Fundenberg and Koistinen, “Hmnan Allotype Detection by
`Passive Hemagglutination, with Special Reference to I1nmu-
`noglobulinAAllotypes” Chapter 103 (pp. 767—774) in Rose
`and Friedman, Manual ofClinical Immunology. Second Edi-
`tion (1980).
`Geisse et al. 1996. Eukaryotic expression systems: a com-
`parison. Protein Expression and Purification 8:27l—282
`(Exhibit 2025; Int. No. 104,532).
`Gillics ct al., “Exprcssion of cloned immunoglobulin gcncs
`introduced into mouse L cells,” Nucl. Acids. Res., vol. 11,
`No. 22, pp. 7982-7997 (1983).
`Glaser et al., “Functional interrelationship between two tan-
`dem E.
`coli
`ribosomal RNA promoters” Nature
`302(59031:74—76 (Mar. 3, 1983).
`Goeddel et al. 1979. Direct expression in Escherichia cali of
`a DNA sequence coding for human growth hormone. Nature
`281(5732):544—8 (Exhibit 2038; Int. No. 104,532).
`Goeddel et al., “Synt iesis of Human Fibroblast Interferon
`by E. coli” Nucleic Acids Research 8(18):4057 4074
`(1980).
`Goeddel, Methods in Enzyinology, vo . 185, AGene Expres-
`sion Teclmology (1990) (Exhibit 1077; Int. No. 104,532).
`Gold et al. 1978. Carcinoembryonic antigen (CEA) in clini-
`cal medicine. Cancer 42:1399—1405 (Exhibit 2135; hit. No.
`104,532).
`Goochee et al. 1991, “The Oligosaccharides of Glycopro-
`teins: BioProcess Factors Affecting Oligosaccharide Struc-
`ture and Their Effect on Glycoprotein 3roperties”, Bio Tech-
`nology 9, 1347-1355 (Exhibit 2187; Int. No. 104,532).
`Goochee, C. F., and T. Monica. 1990. Environmental effects
`on protein glycosylation. Bio Technology 8:421—427
`(Exhibit 2023; Int. No. 104,532).
`Goodman ar1d MacDonald, “Cloning of hormone genes
`from a mixture of cl_)NA molecules” Methods in l:'nzymol-
`ogy 68:75—90 (1979).
`Greipp, P 1992. Advances in the diagnosis and management
`of mycloma. Seminars in Hcmatology 29(3: Suppl. 2):24—45
`(Exhibit 2020; Int. No. 104,532).
`Grillo Lopez et al. 1999. Overview of the clinical develop-
`ment of rituximab:
`first monoclonal antibody treatment
`approved for the treatment of lympl1o111a. Seminars in
`Oncology 26:66—73 (Exhibit 2144; Int. No. 104,532).
`Gross et al, “Bone marrow Purging and Processing,” Interna-
`tional Symposium on Bone Marrow Purging and Processing
`(2nd, Apr. 27 and 28, 1989 Cancun, Mexico) Gross et al.
`(Ed.), Wiley—Liss, NY.
`
`Sanofi/Regeneron Ex. 1026, pg 812
`
`Mylan Ex. 1026, pg 812
`
`

`
`US 6,331,415 C1
`Page4
`
`1998. Monoclonal Antibody Based
`Grossbard, M.L.
`Therapy of Cancer. Marcel Dekker, p. 451 (Exhibit 2094;
`Int. No. 104,532).
`Gruss, P., et al., “Simian virus 40 tandem repeated sequences
`as an element of the early promoter,” Proc. Natl. Acad. Sci.,
`78:943—47 (1981).
`P abara et al. “Rauscl1er Murine Leukemia Virus: Molecular
`Cloning of Infectious Integrated Proviral DNA,” J. ofVirol-
`ogy, vol. 44, No.2, pp. 731 735 fl\Io.v 1982).
`Palc ct al. 1985. Rcactivity of rat monoclonal antibody
`CAMPATH—I with human leukemia cells and its possible
`aoplication for autologous bone marrow transplantation.
`British Journal of Hematology 60(l):41—8 (Exhibit 2074;
`Int. No. 104,532).
`k ale et al. 1988. Remission induction in non Hodgkin lyin-
`phoma with rcshapcd human monoclonal antibody CAM-
`PATH—I H. Lancet 2 (8625): 139-L1399 (Exhibit 2015 and
`1024; Int. No. 104,532).
`Pale et al., 1990. The Campath—I antigen (CDw52). Tissue
`Antigens 35:118—127 (Exhibit 2049 Int. No. 104,532).
`Pale, “Effects of Monoclonal Anti
`lymphocyte Antibodies
`in Vivo in Monkeys and Humans”. Mol Biol Med (1983) 1.
`321—334 (Exhibit 2240; Int. No. 104,532).
`Pale. Progress Report (May 199(LDec. 31, 1990). MRC
`Wellcoine Therapeutic Antibody Center (Exhibit 1072; Int.
`No. 104,532).
`Pamilton, R., “Application of engineered chimeric antibod-
`ies to the calibration of human antibody standards” Annales
`de Biologie Clinigue 49 (4):242—248 (1991).
`P arris “Expression of Eukaryotic Genes in E. calf” Genetic
`Engineering, R.Vv’illiamson, 4”’ edition pp. 127—185 (1983).
`Farris, et al., Proceedings of the 34tl1 Oliolo Conference,
`Eilat, Israel (1990) (Exhibit 1073; Int. No. 104,532).
`Paynes and Weissmarm, “Constitutive,
`long—term produc-
`tion of human interferons by hamster cells containing mul-
`tiple copies ofa cloned interferon gene,” (1983) Nucl. Acid.
`Res., vol. 11 No. 3, pp. 687—706 (Exhibit 1109; Int. No.
`104,532).
`Hodge, J.W. 1996. carcinoembryonic antigen as a target for
`cancer vaccines. Cancer
`Immunol
`and
`Imniunother
`431127-134 (Exlibit 2032; Int. No. 104,532).
`Hutchins et al., Proc. Natl. Acad. Sci. USA, vol. 92, pp.
`11980—11984 (1995).
`Huynh ct al., 1984. Constructing and screening cDNA
`libraries in kgt IO and kgtl 1. DNA Cloning, vol. I—A prac-
`tical Approach 49—78. Glover, D(Editor), IRL Press, Oxford
`(Exhibit 2050; Int. No. 104,532).
`Jackson and Davis, “Quantitation of Iinmunoglobulins,”
`Chapter 14 (pp. 109—120) in Rose and Friedman, i\/[anual of
`Cliniral Immunology, Second Edition (1980).
`Jefferis et al. 1998. IgG—Fc—mediated effector functions:
`molecular definition of interaction sites for effector ligands
`and thc rolc of glycosylation.
`Immunological Rcvicws
`163:59 76 (Exhibit 2095; Int. No. 104,532).
`Joziasse, et al., 2000 “a3Iialactosylated glycoproteins can
`bind to the hepaticasialoglycoprotein receptor” Eur. J. Bio-
`chem. 267:6501—6508 (Exhibit 1037; Int. No. 104,532).
`Kabat ct al. Scqucnccs of Protcins of Immunological Inter-
`est, Bethesda, MD: National Institute of Health pp. i, xxi,
`xxii (1983).
`Khazaeli, et al., Cancer Research, 51, 5461—5466 (1991)
`(Exhibit 1074; Int. No. 104,532).
`
`Kabat et al., “Sequences of immunoglobulin chains: tabula-
`tion
`and
`analysis
`of
`amino
`acid
`sequences
`of
`precursors, V—regions, C—regions,
`J—chain and [beta]2—
`microglobulins .
`.
`.
`,” The Kabat Database of Sequences of
`Protcins of Innnunological Intcrcst, 1979, Publication No.
`80 2008, p. 185, National Institute of Health, Bethesda,
`MD. (GNE—MED 52680).
`Kaetzel et al. 1985. Expression of biologically active bovine
`luteinizing hormone in Chinese hamster ovary cells. Proc.
`Natl. Acad Sci. USA 82:7280—7283 (Exhibit 2152; Int. No.
`104,532).
`Kagawa Y; J Biol Chem Nov. 25, 1988:263(33):17508—15
`(Exhibit 1153; Int. No. 104,532).
`Kaufman et al. 1987. Coamplification and coexpression of
`human tissueetype plasminogen activator and murine dihy—
`drofolate reductase sequences in Chinese hamster ovary
`cells. Molecular and Cellular Biology 5:175(L1759 (Exhibit
`2075; Int. No. 104,532).
`Khazaeli et al., Manuscript—Frequent Anti—V Region
`Immune Response to Mouse B723 Monoclonal Antibody
`(pp. 25 63).
`Kipriyanov ct al. 1999. Gcncration of recombinant antibod-
`ies. Molecular Biotechnology 12:173—201 (Exhibit 2017:
`Int. No. 104,532).
`Klausner, A. “Genentech makes monoclonal precursors
`from Ecoli” Bio/Technology I(5):396—397 (1983).
`Kohler, G., et al., “Imn1unoglobulin chain loss in hybridoma
`cell lines,” Proc. Natl Acad. Sci.. 77:2197—99 (1980).
`Kohler, G. BioScience Reports 5:533—549 (1985) (Plaintiff
`Exhibit 1108, Case No. CIV S 00 1252 WBS GGH).
`Krag et al., J. Biological Chemistry, Vol. 257, No. 14, p.
`8424 (1983) (Exhibit 1115; Int. No. 104,532).
`Krag, J. Biol. Chem. 254:9167—9177 (1979) (Exhibit 1043;
`Int. No. 104,532).
`Krolick et al. 1982. In vivo therapy of a Murine B cell tumor
`(BCI, I) using antibody—ricin a chain immunotoxins. J Exp.
`Med. 155:1797—1809 (Exhibit 2122; Int. No. 104,532).
`Kyle, “Classification and Diagnosis of Monoclonal Gannno-
`pathies,” Chapter 16 (pp. 135—150) in Rose and Friedman,
`Manual 0fCli1zical Immimology, Second Edition (1980).
`I.evy, R. and R.A. Miller. 1983. Biological and clinical
`implications of lymphocyte hybiidomas: tumor therapy with
`monoclonal
`antibodies. Ann. Rev. Med—34:107—1 16
`(Exhibit 2121; Int. No. 104,532).
`Lifely et al., Glycobiology, vol. 5 No. 8; 813-822, 1995
`(Exhibit 1170; Int. No. 104,532).
`Lingappa et al. 1980. Signal sequences for early events in
`protein secretion and membrane assembly. Ann. NYAcad.
`Sci. 343:356—61 (Exhibit 2147; Int. No. 104,532).
`Linscott’s Directory (fonnerly Catalog) of Immunological
`and Biological Reagents, second edition 1982—83, pp. 1—57.
`LoBuglio and Saleh, Am. J. Medical Sciences, Sep. 1992
`vol. 304. No. 3. pp. 214—224 (Exhibit 1160: Int. No. 104,
`532).
`Liu et al., “Expression of mouse: human immunoglobulin
`heavywhain cDNA in lymphoid cells” Gene 54(1):33—40
`(1987).
`M.D. Pegram et al.. “Antibody dependent cell—mediated
`cytotoxicity in breast cancer patients in Phase lll clinical
`trials of a humanized anti—HER2 antibody”, Proc Am.
`Assoc. Cancer Res., 1997, 38:602 (#4044) (Exhibit 2248;
`Int. No. 104.532).
`
`Sanofi/Regeneron Ex. 1026, pg 813
`
`Mylan Ex. 1026, pg 813
`
`

`
`US 6,331,415 C1
`Page 5
`
`Ma, S. and W. Nashabeh. 1999. Carbohydrate analysis of a
`chimeric recombinant monoclonal antibody by capillary
`electrophoresis with laser—induced fluorescence detection.
`Analytical Chemistry 71 :5185—5 192 (Exhibit 2145; hit. No.
`104,532).
`Maniatis, T., E.F. Fritsch, and J. Sambrook. 1982. Table of
`Contents; “Extraction, Purification, and Analysis of MRNA
`from Eukaiyotic Cells”. 187—209; “Synthesis and Cloning
`of CDNA”, 21 1—246; and “Construction of Genomic Librar-
`ics”, 269—307. In Molecular Cloning A Laboratory Manual,
`\Iew York: Cold Spring Harbor Laboratory (Exhibit 2008;
`Int. No. 104.532).
`\/Iargulies et al., “Regulation of immunoglobu in expression
`i11 mouse myeloma cells” I111n1u11oglobulin Expression pp.
`7s1—791 (1977) (GNP.—l\/[FD 31462).
`Vlarx, J. Science 2292455456 (1985) (I‘lainti’" Exhibit No.
`1118, Case No. CIV S4)0—1252 WBS GGH).
`\/Iartinis et al., “Monoclonal antibodies with dual antigen
`specificity” Oncology pp. 3l1—316.
`\/Iatsuuchi et al. 1981. An analysis of heavy chain glycopep-
`tides of hybridoma antibodies: correlation between antibody
`specificity and sialic acid content. Journal of Immunology
`127(5):2188 90 (Exhibit 2060; Int. No. 104,532).
`\/Iercola et al., “Transcriptional Enhancer Elements in the
`\/Iouse Immunoglobulin Heavy Chain Locus,” Science, vol.
`221, No. 4611, p. 663-65 (Aug. 12, 1983).
`Vleredith et al., J. Nucl. Med, Jan. 1992, 33:23—29 (pp.
`13—19).
`\/Icrcdith ct al., J. Nucl. Mcd., vol. 33, No. 9: 1648r1653,
`Sep. 1992.
`al., Hum. Antibod. Hybridomas,
`et
`\/Ieredith,
`4:19(L197 (Exhibit 1083; Int. No. 104,532).
`\/Iiles Biochemicals 1979—80, p. 140—142.
`\/Iiller et al., “Transfection of human lymphoblastoid cells
`with herpes simplex viral DNA,” Proc. Natl. Acad. Sci., vol.
`76, No. 2, pp. 949—953 (Feb. 1979).
`Vlorell et al. 1971. '1'he role of sialic acid in detennining the
`survival of glycoprotcins in the circulation. J. Biol Chcm.
`246:1461 1467 (Exhibit 21 17; Int. No. 104,532).
`\/Iorrison SL, et al., “A mouse myeloma variant with a defect
`in light chain synthesis," Eur. J Immunol., 9:461—65 (1979).
`\/Iorrison et al. 1988. Genetically engineered antibody mol-
`ecules: new tools for cancer therapy. Cancer Investigation
`6(2):185—92 (Exhibit 2085; I11t. No. 104,532).
`\/Iorrison et al. 1988. Production and characterization of
`genetically engineered antibody molecules. Clinical Chem-
`istry 34(9): 1 668—75 (Defendant Exhibit 5009, Case No. CIV
`S 00 1252 WBS GGH).
`\/Iorrison,
`S. Hospital Practice 24(10):65w80
`(GNE—MED 077476).
`\/Iorrison, S., “In vitro antibodies: strategies for production
`and
`application” Ammal Review of
`Immunology
`10:239—265 (1992).
`\/Iulligan. RC, et al., “Selection for animal cells that express
`the Escherichia coli gene coding for xanthine—guanine phos-
`phoribosyltransferase,” Proc. Natl. A cad. Soil, 78 :2072—76
`(1980).
`\/Iunro, “Uses of chimeric antibodies,” Naturc 3122597
`(1984).
`\Ieuberger, M. TIBS 347-349 (1985) (Plaintiff Exhibit 1130
`(Case No. CIV S4)0—1252 WBS GGH).
`\Ieuhaus et al.,
`JACC 14:1566—1569 (Nov. 15, 1989)
`(Exhibit 1032; Int. No. 104,532).
`
`(1989)
`
`1993,
`
`Neumaier et al., Cancer Research 50:2128—2134 (Apr. 1,
`1990) (Exhibit 1013; Int. No. 104,532).
`Nose, M. and H. Wigzell. 1983. Biological significance of
`carbohydrate chains on monoclonal antibodies. Proc. Natl.
`Acad. Sci. USA 80:6632—6636 (Exhibit 2022; Int. No. 104.
`532).
`Oi et al., “Immunoglobulin Gene Expressin in Transformed
`Lymphoid Cells,” Proc. Natl. Acad. Sci., vol. 80, No. 3, p.
`825—59 (Feb. 1, I983).
`Oi & Morrison BioTechmques 4(3):214 221 (1986) (Plain-
`tiff Exhibit 1135, Case No. CIV S—00—1252 WBS GGH).
`Oldl1a1n, R. 1983. Monoclonal antibodies in cancer therapy.
`Journal of Clinical Oncology 1:582—590 (Exhibit 2119; Int.
`104,532).
`Orfila et al., “Immunofiuorescence study of “non—idio—
`pathic” renal amyloidosis,” Hum. Pathol.
`14(4):362—7
`(1983).
`Pcakman ct al., Hum. Antibod. Hybridomas 5:65—74 (1994)
`(Exhibit 1038; Int. No. 104,532).
`Page et al., Biotech, 9:64—68 (1991).
`Picard et al., “Correct transcription of a cloned mouse
`immunoglobulin gene in vivo,” Proc. Natl. Acad. Sci., vol.
`80, pp. 417—421 (Jan. 1983).
`Potamianos et al. 2000, Radioimmunoscintigraphy and
`Radioimmunotherapy in Cancer: Principles and Application,
`Anticancer Research 20, 925—948 (Exhibit 2185, Int. No.
`104,532).
`Primus et al., Cancer Immunol. Immunotherapy (1990)
`31:349—357 (Exhibit 1164; Int. No. 104,532).
`Queen and Baltimore, “lmmunoglobulin gene transcription
`is activated by downstream scqucncc clcmcnts” Ccll
`33(3):741 748 (Jul. 1983).
`Queen, C, “Comparison of mouse and human V—l<appa
`domains” (Submitted by PDL Mar. 27, 1997).
`Queen, C., “Comparison of human and mouse VH domains”
`(Submitted by PDL on Mar. 27, 1997.
`Rademacher et al. (1988) Ann. Rev. Biochem. 57:785—838
`(Exhibit 2165; Int. No. 104,532).
`Raju et al. 2000. Species—specific variation in glycosylation
`of IgG: evidence for the species—specific sialylation and
`branch—specific galactosylation and importance for engi-
`neering recombinant glycoprotein therapeutics. Glycobiol-
`ogy 10(5):477—486 (Exhibit 2027; Int. No. 104,532).
`Reff et al., Blood, vol. 83, No. 2, pp. 435—445 (1994)
`(Exhibit 1111; Int. No. 104,532).
`Renner et al. 1997. Monoclonal antibodies in the treatment
`of non—Hodgkin’ s lymphoma: recent results and future pros-
`pects. Leukemia 11(2):S55—S59 (Exhibit 2019; Int. No. 104,
`532).
`Rhodes and Birch Biotechnology 6:518, 521, 523 (1988)
`(Exhibit 1046: Int. No. 104,532).
`Rhodes, Adv. Anim. Cell. Biol. Technol. Bioprocess.,
`472—74 (1988) (Exhibit 1045; Int. No. 104,532).
`Riechmann et al. 1988. Expression of an antibody Fv frag-
`ment
`in myeloma cells. Journal of Molecular Biology
`203(3):825 8 (Exhibit 2087; Int. No. 104,532).
`Riechmann et al. 1988. Reshaping human antibodies for
`therapy. Nature 322:323—327 (Exhibit 1022: Int. No. 104,
`532).
`Rosen et al. 1983. Application of monoclonal antibodies to
`tumor diagnosis and therapy. Annals of Clinical and Labora-
`tory Science 13:173—184 (Exhibit 2120; Int. No. 104,532).
`Routledge et al., Eur. J. Immunol. 1991, 21:2717—2725
`(Exhibit 1068; Int. No. 104,532).
`
`Sanofi/Regeneron Ex. 1026, pg 814
`
`Mylan Ex. 1026, pg 814
`
`

`
`US 6,331,415 C1
`Page 6
`
`Schein et al., “For1nation of Soluble Recombinant Proteins
`in Escherichia coli is Favored by Lower Growth Tempera-
`ture” BioTechnoloqy 6:291—294 (1988).
`Schein, Catherine H., “Production of soluble recombinant
`proteins in bacteria” Bio/Technology 7:1 141—l 149 (1989).
`Sekigawa et al., J. Virology 64:5l94—5198 (Oct. 1990)
`(Exhibit 1056; Int. No. 104,532).
`Sheeley et al., Analytical Biochemistry 247, 102—1 10 (1997)
`(Exhibit 1096; Int. No. 104,532).
`Sidman. C. 1981. Differing requirements for glycosylation
`in the secretion of related glycoproteins is determined nei-
`ther by the producing cell nor by the relative number of
`oligosaccharide
`units.
`Journal
`of
`Biol.
`Chem.
`256(18):9374—9376 GExhibit 2100; Int. No. 104,532).
`Solomon, “Bence—Jones Proteins and Light Chains of
`Immunoglobulins,” Scand. J. Imn1uno1., vol. 5, 685—695
`(1976).
`Southern, PJ et al. “Transformation of mammalian cells to
`antibiotic resistance with a bacterial gene under control of
`the SV40 early region promoter," J. Molec. App]. Genez..
`1:327—41 (1982).
`Spelhnan et al., 1989, J. Bio. Chem. 264:14100—14111
`(Exhibit 1151; Ii1t.No. 104,532).
`Stafford and Queen, “Ce1l—type specific expression of a
`transfected immunoqlobulin qene” Nature 306(5938)—
`77—79 (Nov. 3, 1983).
`Stevenson et al., 1989, A Chimeric Antibody \Vith Dual Fc
`Regions (bisFabFc) Prepared by Manipulations at the IgG
`Hinge. Antifiancer Drug Design 3. 219-230 (Exhibit 2182;
`Int. No. 104.532).
`Stevenson et al., Blood 77:1071—1079 (Mar.
`(Exhibit 1026; Int. No. 104,532).
`Sunnners et al., “Stable expression in mouse cells ofnuclear
`neoantigen after transfer of a 3.4—megadalton cloned frag-
`ment of Epstein—Barr virus DNA,” Proc. Natl. Acad. Sci.,
`vol. 79, pp. 5688 5692 (Sep. 1982).
`Sun ct al. 1987. Chimcric antibody with human constant
`regions and mouse variable regions directed against carcino-
`ma—associated antigen 17—IA. Proc. Natl. Acad. Sci.
`84(l):2l4—8 (Exhibit 2080; Int. No. 104,532).
`".E. Hotaling et al., “The humanized anti—HER2 antibody
`rhuMAb IIER2 mediates antibody dependent cell—mediated
`cytotoxicity via Fci,/R III”, Proc. Am. Assoc. Canccr Rcs.,
`996, 37:471 (#3215).
`Takeda et al. Nature 314:452—454 (1985) (Plaintiff Exhibit
`171, Case No. CIV S4)0—1252 WBS GGH).
`"akei et al. 1980. Monoclonal antibody H9/25 reacts with
`functional subsets of T and B cells: killer, killer percursor
`and plaque—forming cells. European Journal of Immunology
`0(7):503—9 (Exhibit 2042; Int. No. 104,532).
`"akeuchi et al., J. Biol. Chem., 263:3657—3663, (Exhibit
`152; Int. No. 104,532).
`‘an et al. 1985. A human—mouse chimeric in immunoglobu-
`lin gcnc with a human variable region is cxprcsscd in mousc
`myeloma cells.
`Journal of immunology 135(5):3564—7
`(Exhibit 2078; Int. No. 104,532).
`"aniguchi et al., “Expression of the Human Fibroblast Inter-
`feron Gene in Escherichia Cali”, Proc. Natl. Acad. Sci.
`USA, 77(9):5230—5233 (Sep. 1980).
`' arentino et al. 1974. The release of intact oligosaccharides
`from specific
`glycoproteins
`by
`F.ndo—o—N—acetylglu-
`cosaminidase H.
`Journal
`of Biological Chemistry
`249:818£24 (Exhibit 2116; Int. No. 104,532).
`
`1. 1991)
`
`Tomimo et al., “Specificity of eluted antibody from renal
`tissues of patients with IgA nephropathy,” Am. J. Kidney
`Dis. 1(5):276—80 (1982).
`Trill et al. 1995. Production of monoclonal antibodies in
`COS and CHO cells. Current Opinion in Biotechnology 6:
`553—560 (Exhibit 2108; Int. No. 104,532).
`Tsuchiya et al. 1989. Effects of galactose depletion from
`oligosaccharide chains on immunological activites ofhuman
`IgG. Journal of Hematology 16:285—90 (Exhibit 2092; Int.
`No. 104,532).
`Urlaub, G. and L. A. Chasin. 1980. Isolation of Chinese
`hamster cell mutants deficient in dihydrofolate reductase
`activity. Proc. Natl. Acad Sci. USA 77:4216—4220 (Exhibit
`2031; Int. No. 104,532).
`Van Brunt, J. 1986. There’s nothing (quite) like tie real
`thing. Bio/Technology 4:835-839 (Exhibit 2024; Int. No.
`104,532).
`Van Nagell et al. 1980. Radioimmunodetection of primary
`and metastasis ovarian cancer using radiolabeled antibodies
`to carcinoembryonic antigen. Cancer Research 40(3):502—6
`(Exhibit 2043; Int. No. 104,532).
`Verhoeyen et al. 1988. Reshaping human antibodies: graft-
`ing an antilysozyme activity. Science 239(4847):1534—6
`(Exhibit 2089; Int. No. 104,532).
`Villicrs ct al. “Transcriptional ‘cnhanccrs’ from SV40 and
`polyoma virus show a cell type preference,” Nucl. Acids
`Res., vol. 10, No. 24, p. 7965—76 (1982).
`Wagener, Shively publication (Bates Nos. 0927—0934)
`(GNE—MED—01 5 97).
`Wallick et al. 1988. Glycosylation of a VH residue of a
`monoclonal antibody against alpha (1 l6) dextran increases
`its affinity for antigen. Journal Of Experimental Medicine
`168(